Cover Image
QR Code

Pyoderma gangrenosum: an update.

Pyoderma gangrenosum (PG) can be differentiated into classic and atypical forms. The classic form is characterized by ulcers and the atypical form by deep erosions with bullous blue-gray margins. Pathergy, the development of cutaneous lesions at sites of trauma, is a common feature of both forms of...

Full description

Published in:Rheumatic Disease Clinics of North America Vol. 33; no. 4; pp. 787 - 804
Main Authors: Callen JP, Jackson JM
Format: Journal Article
Published: W B Saunders 2007 Nov
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105859416&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105859416
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0889857X
        4GH
      jtl: Rheumatic Disease Clinics of North America
      issn: 0889857X
      maglogo: N
    pubinfo:
      dt: 2007 Nov
      vid: 33
      iid: 4
      pid: 1351
      pub: W B Saunders
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        105859416
        2009752997
        NLM18037117
        105859416
      ppf: 787
      ppct: 17
      formats:
      tig:
        atl: Pyoderma gangrenosum: an update.
      aug:
        au:
          Callen JP
          Jackson JM
        affil: Division of Dermatology, University of Louisville, 310 East Broadway, Louisville, KY 40202, USA. jefca@aol.com
      sug:
        subj:
          Pyoderma Gangrenosum Diagnosis
          Pyoderma Gangrenosum Drug Therapy
          Diagnosis, Differential
          Prognosis
      ab: Pyoderma gangrenosum (PG) can be differentiated into classic and atypical forms. The classic form is characterized by ulcers and the atypical form by deep erosions with bullous blue-gray margins. Pathergy, the development of cutaneous lesions at sites of trauma, is a common feature of both forms of PG. Approximately 50% of patients who have PG have underlying systemic diseases, most commonly inflammatory bowel disease, myeloproliferative disorders, and various forms of inflammatory arthritis. The diagnosis of PG is one of exclusion. The management of this disorder begins with treatment of any underlying disease and local or systemic glucocorticoids or immunomodulating therapies.Copyright © 2007 by Elsevier Inc.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N